script.reportAU
Sponsor

Amgen Australia

76 PBAC submissions on file, active 2005–2025. 70% have been recommended.

Submissions
76
2005 → 2025
Win rate
70 %
53 recommended of 76 bucketable
Drugs
19 · 17 listed
unique molecules submitted
PBS spend captured
FY-latest govt benefit on owned drugs

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

Therapy area mix

Oncology 28
Endocrinology 16
Haematology 13
Cardiovascular 12
Dermatology 3
Rheumatology 2
Ophthalmology 1
Immunology 1

Activity by year

2005 (1) · 2006 (2) · 2007 (3) · 2008 (3) · 2009 (2) · 2010 (2) · 2011 (1) · 2012 (1) · 2013 (5) · 2014 (2) · 2015 (3) · 2016 (8) · 2017 (4) · 2018 (10) · 2019 (8) · 2020 (5) · 2021 (2) · 2022 (5) · 2023 (3) · 2024 (4) · 2025 (2)

Rejection patterns

Across 20 Not recommended decisions on file.

Open on full dashboard →